about
Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice GuidelineLack of Understanding of Cervical Cancer and Screening Is the Leading Barrier to Screening Uptake in Women at Midlife in Bangladesh: Population-Based Cross-Sectional Survey.Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.Association between knee cartilage volume and bone mineral density in older adults without osteoarthritis.Negative beliefs about low back pain are associated with high pain intensity and high level disability in community-based women.The therapeutic use of androgens in women.Do intracrine mechanisms regulate aromatase expression?Phytoestrogens in health and disease.Circulating androgen levels and self-reported sexual function in women.Testosterone effects on the breast: implications for testosterone therapy for women.Androgen levels in adult females: changes with age, menopause, and oophorectomy.Total cholesterol and triglycerides are associated with the development of new bone marrow lesions in asymptomatic middle-aged women - a prospective cohort studyFactors affecting progression of knee cartilage defects in normal subjects over 2 years.Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment.The effects of tibolone on mood and libido.When to suspect androgen deficiency other than at menopause.Greater superior than inferior parietal lobule activation with increasing rotation angle during mental rotation: an fMRI study.Tibial cartilage volume change in healthy postmenopausal women: a longitudinal study.Tibial plateau size is related to grade of joint space narrowing and osteophytes in healthy women and in women with osteoarthritis.Factors associated with magnetic resonance imaging defined patellar tendinopathy in community-based middle-aged women: a prospective cohort study.The use of testosterone after menopause.Androgen insufficiency in women: diagnostic and therapeutic implications.Postmenopausal testosterone therapy and breast cancer risk.Osteoarthritis and the postmenopausal woman: Epidemiological, magnetic resonance imaging, and radiological findings.Treatment of menopausal symptoms: what shall we do now?Endocrine aspects of female sexual dysfunction.Homocysteine, estrogen and cognitive decline.Androgen therapy in women: an Endocrine Society Clinical Practice guideline.What is the clinical and ethical importance of incidental abnormalities found by knee MRI?High sensitivity C-reactive protein is associated with lower tibial cartilage volume but not lower patella cartilage volume in healthy women at mid-life.Use of a cancer registry is preferable to a direct-to-community approach for recruitment to a cohort study of wellbeing in women newly diagnosed with invasive breast cancerLong-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialDHEA therapy for women: effect on sexual function and wellbeing.Association between meniscal tears and the peak external knee adduction moment and foot rotation during level walking in postmenopausal women without knee osteoarthritis: a cross-sectional study.Prevalence and incidence of urinary incontinence in women: review of the literature and investigation of methodological issues.Androgen replacement therapy in androgen-deficient women with hypopituitarism.Lack of knowledge of hormone receptor status and use of endocrine therapy in invasive breast cancer.DHEA for postmenopausal women: a review of the evidence.Endocrine aspects of women's sexual function.Drugs for the treatment of menopausal symptoms.
P50
Q22306200-50F499DA-E393-4EE3-BA29-54DF8C14A871Q30202029-7ABE1EFF-354A-442D-A2F9-4C09A3F100F9Q30278558-5A54067F-AA5E-4652-9D83-9CD09BA8DE6CQ33200063-0AFDFFF6-0042-42A3-996E-6740334FD139Q33382542-92785BF5-0E50-4865-BB00-0E76BB7A2039Q33694952-C4A6AF14-5303-4CD7-94E9-A225129D1B94Q33695092-DBF7A17E-2D0B-4648-8CDB-C29630E3353EQ33766885-280A182C-DE2A-4A52-92DE-A52910E9A8FFQ33988402-0521CCBA-A12D-44C4-B15B-3F6C77B0F561Q34324964-F8D1A0DA-2CF6-4A83-8B4F-3C2861F50D37Q34411038-B9F116DA-7CFE-4C90-A070-25CBD86EEEC8Q34413298-777FA922-E402-4183-81B4-A564AAB0D661Q34454530-075B9E6F-AD68-4E49-A85E-123DDFE2DDEEQ34590967-DC23A404-8379-48C1-A7FF-DB5598D5FB1EQ34612656-2D82EE1F-A19C-4968-8A79-456DE3A826F3Q34635758-3D079569-281D-4DE2-9907-FC17C9303B3EQ35009107-F3217BD4-5788-4410-BADC-DE3B5BFDFEB3Q35553976-7E61AAE8-A2E3-47B2-B1FA-8A40B29951A2Q35555718-C6B7371F-2D32-4BB0-A57E-12DF992BF19EQ35737840-6D636765-1923-46A5-B395-14A02A9ED7A6Q35810676-A0A5F010-3C90-47DB-8488-DA68A30C07E2Q35857314-9CD13140-EC96-46A0-B6B7-365A1618016FQ35942155-5C6C3222-4429-4C0D-9800-AD461E371CAFQ35988954-711CA8F7-0BAD-4000-8B24-F9AA549FFF51Q36213129-D76C0C63-F8F3-4839-8CFB-0D2F1220D637Q36372501-2148F310-143A-4042-980C-EFEF8E443B7EQ36477867-246F4915-6BBB-4C2D-921F-912D5633E99FQ36612578-3E9BB535-5B79-4537-BE76-A3CCF4A766D0Q36641512-68C92166-30A9-453B-9683-DEA30D20CA46Q36641586-3DDD00C2-186F-45E6-8711-DCECA66B3F40Q36675785-F700DBD4-B9E5-4DDE-BC60-FD08117889F8Q36680024-48F75019-FEAF-4E98-B397-2CEAD1ABA81BQ36701873-3148522B-4CBE-4B96-963E-DBD639BE01ACQ36790365-BCECE267-7393-41D0-8A8A-ADE5A0FE8DAAQ37096204-0435B0AB-3845-4A75-B15A-6FC70106376CQ37288723-13001F40-8E0F-4936-BC96-C09A19EB395FQ37665853-E973FE75-5CA4-4CE3-BB56-26E4456D5A7BQ37678684-08B884E0-D85D-4C0B-AC7B-E22D4BA58BDBQ37679273-62BCC44C-D01E-44FB-8EE1-594F29B54F42Q37735189-85E30BDB-6C4F-454C-9FD0-2FED47BD78D5
P50
description
onderzoeker
@nl
women's health researcher
@en
հետազոտող
@hy
name
Susan R. Davis
@ast
Susan R. Davis
@en
Susan R. Davis
@es
Susan R. Davis
@sl
type
label
Susan R. Davis
@ast
Susan R. Davis
@en
Susan R. Davis
@es
Susan R. Davis
@sl
altLabel
Susan Davis
@en
prefLabel
Susan R. Davis
@ast
Susan R. Davis
@en
Susan R. Davis
@es
Susan R. Davis
@sl
P106
P1153
24486333300
P21
P31
P496
0000-0002-2955-0415